Idera, GSK to collaborate on renal disease

Wednesday, November 25, 2015

Idera Pharmaceuticals, a Cambridge, Mass.-based clinical-stage biopharmaceutical company developing toll-like receptors and RNA therapeutics for patients with cancer and rare diseases, has entered into an exclusive worldwide collaboration and license agreement with GlaxoSmithKline to research, develop and commercialize selected molecules from Idera’s third-generation antisense platform for the treatment of selected targets in renal disease.

[Read More]

$100M Dementia Discovery Fund launches

Wednesday, October 21, 2015

The Dementia Discovery Fund, a new initiative designed to speed up the discovery and development of new treatments for dementia, has launched after securing $100 million backing from worldwide investors. The U.K. government’s Department of Health, Alzheimer’s Research U.K. and pharmaceutical companies including Biogen, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer and Takeda have joined forces to support the innovative new fund.

[Read More]

PeptiDream, Sanofi collaborate

Monday, September 14, 2015

PeptiDream, a public Tokyo-based biopharmaceutical company, has announced a multi-target discovery and optimization collaboration with Sanofi. PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi. Sanofi will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration.

[Read More]

PPD adds Michael Gold to neuroscience team

Thursday, September 10, 2015

Pharmaceutical Product Development (PPD) has announced that Michael Gold, M.D., has joined PPD’s neuroscience team to serve as vice president of global product development, strengthening the company’s ability to help biopharmaceutical clients manage the complex world of nervous system disorders and deliver therapies more efficiently and cost-effectively.

[Read More]